Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Achaogen
Achaogen Signs $26.6 Million Contract With NIAID for Development of New Therapy to Treat Resistant Strains of NIAID Category a and B Priority Pathogens
March 20th, 2009
Achaogen, a clinical stage biopharmaceutical company addressing the issue of multi-drug resistant bacterial infections through the discovery and development of innovative broad-spectrum antibiotics, announced that it has been awarded a contract worth up to $26.6 million over five years from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services. This award will fund the discovery and development of proprietary Achaogen compounds to combat biothreat strains of Gram-negative bacteria such as Yersinia pestis, the causative agent of bubonic plague, and Francisella...
Source: Health Business Week (2009-03-20)
|
